Skip to content

Research at St Andrews

A prognostic index for operable, node-negative breast cancer

Research output: Contribution to journalArticle

DOI

Author(s)

M McCallum, C Baker, K Gillespie, Brian Cohen, H Stewart, R Leonard, D Cameron, R Leake, J Paxton, A Robertson, C Purdie, A Gould, Michael Steel

School/Research organisations

Abstract

Clinical data and samples from patients diagnosed, more than 10 years previously, with operable node-negative breast cancer (participants in the Scottish Adjuvant Tamoxifen trial), were revisited, Cases with two distinct categories of outcome were selected; more than 10 years disease-free survival ('good outcome') or distant relapse within 6 years of diagnosis ('poor outcome'). An initial set of cases was analysed for a range of putative prognostic markers and a prognostic index, distinguishing the two outcome categories, was calculated. This index was then validated by testing its predictive power on a second, independent set of cases. A combination of histological grade plus immunochemical staining for BCL-2, p27 and Cyclin D 1, generated a useful prognostic index for tamoxifen-treated patients but not for those treated by surgery alone, The value of the index was confirmed in a second set of tamoxifen-treated, early stage breast cancers. Over-all, it correctly predicted good and poor outcome in 79 and 74% of cases, respectively (odds ratio 11.0). Other markers assessed added little to prediction of outcome. In the case of molecular assays, sensitivity and reliability were compromised by the age of the tissue specimens and the variability of fixation protocols. In selecting patients for adjuvant systemic chemotherapy, the proposed index improves considerably on current international guidelines and matches the performance reported for 'gene-expression signature' analysis. (C) 2004 Cancer Research UK.

Close

Details

Original languageEnglish
Pages (from-to)1933-1941
Number of pages9
JournalBritish Journal of Cancer
Volume90
DOIs
Publication statusPublished - 17 May 2004

    Research areas

  • markers, immunohistochemistry, grade, BCL-2, cyclin DI, UROKINASE-PLASMINOGEN-ACTIVATOR, FOLLOW-UP, CYCLIN-E, ADJUVANT TAMOXIFEN, GENETIC CHANGES, RECEPTOR STATUS, C-MYC, EXPRESSION, CHEMOTHERAPY, HER-2/NEU

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Why do women not return family history forms when referred to breast cancer genetics services? A mixed-method study

    Hanning, K., Steel, C. M., Goudie, D., McLeish, L., Dunlop, J., Myring, J., Sullivan, F., Berg, J., Humphris, G. M. & Ozakinci, G., Oct 2015, In : Health Expectations. 18, 5, p. 1735-1743

    Research output: Contribution to journalArticle

  2. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status

    Moller, P., Evans, DG., Reis, MM., Gregory, H., Anderson, E., Maehle, L., Lalloo, F., Howell, A., Apold, J., Clark, N., Lucassen, A. & Steel, C. M., 1 Sep 2007, In : International Journal of Cancer. 121, 5, p. 1017-1020 4 p.

    Research output: Contribution to journalArticle

  3. Monitoring phyto-oestrogen exposure in patients with breast cancer after diagnosis

    Gilmour, A., Ritchie, M. R., Mackinnon, L. J., Wong, V., Charlton, C., Steel, C. M., Gates, S. E. E., Smith, J. & Gibbs, T. J., 2007, In : Proceedings of the Nutrition Society . 66, p. 31A-31A 1 p.

    Research output: Contribution to journalArticle

  4. Analysis of referrals to a multi-disciplinary breast cancer genetics clinic: practical and economic considerations

    Reis, M. M., Young, D., McLeish, L., Goudie, D., Cook, A., Sullivan, F., Vysny, H., Fordyce, A., Black, R., Tavakoli, M. & Steel, M., Nov 2006, In : Familial Cancer. 5, 4, p. 297-303 7 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Comparing uptake across breast, cervical and bowel screening at an individual level: a retrospective cohort study

    McCowan, C., McSkimming, P., Papworth, R., Kotzur, M., McConnachie, A., Macdonald, S., Wyke, S., Crighton, E., Campbell, C., Weller, D., Steele, R. JC. & Robb, K. A., 15 Oct 2019, In : British Journal of Cancer. 121, 8, p. 710–714 5 p.

    Research output: Contribution to journalArticle

  2. Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models

    Martínez-Pérez, C., Ward, C., Turnbull, A. K., Mullen, P., Cook, G., Meehan, J., Jarman, E. J., Thomson, P. I. T., Campbell, C. J., McPhail, D., Harrison, D. J. & Langdon, S. P., 13 Apr 2016, In : British Journal of Cancer. 114, 8, p. 905-916

    Research output: Contribution to journalArticle

  3. Aspirin use and survival after the diagnosis of breast cancer: A population-based cohort study

    Fraser, D. M., Sullivan, F. M., Thompson, A. M. & McCowan, C., 29 Jul 2014, In : British Journal of Cancer. 111, 3, p. 623-627 5 p.

    Research output: Contribution to journalArticle

  4. Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer

    Koussounadis, A., Langdon, S. P., Harrison, D. J. & Smith, V. A., 10 Jun 2014, In : British Journal of Cancer. 110, 12, p. 2975-2984 10 p.

    Research output: Contribution to journalArticle

  5. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality

    Makubate, B., Donnan, P. T., Dewar, J. A., Thompson, A. M. & Mccowan, C., 1 Apr 2013, In : British Journal of Cancer. 108, 7, p. 1515-1524 10 p.

    Research output: Contribution to journalArticle

ID: 352008

Top